UNICEF is preparing to issue the second Call for Offers for Pneumoccal Vaccines for GAVI-eligible countries under the Advance Market Commitment (AMC) with the objective of meeting the demand for the next five years. A pre-tender meeting is therfore scheduled to take place in UNICEF Supply Division, Copenhagen, on March 10th 2011.
An AMC is an innovative new financing strategy designed to accelerate access to lifesaving new vaccines and medicines in developing countries - the AMC pilot is focusing on the development and availability of pneumococcal vaccines. Donor countries and the Bill and Melinda Gates Foundation have committed US$1.5 billion to support this initiative (for more information, seehttp://www.vaccineamc.org/pneu_amc.html) to develop supply capacity of 200 million doses on an annual basis.
The AMC is intended to use funds committed by donors to guarantee the price of yet to be developed vaccines, thus providing manufacturers with more certain market conditions, the incentive to make the considerable investment required for new vaccines and the capacity to supply vaccines in the quantities required by developing countries. The goal is to create a self-sustaining marketplace with affordable prices for eligible countries over time.
UNICEF issued the first Call for Offers in September 2009 and entered into long term contracts with two suppliers totalling 60 million doses of vaccines on an annual basis to be supplied from 2013. As of today, 19 out of 72 eligible countries have been approved by GAVI to receive funding for introduction of pnemococcal vaccines in their programmes and introductions are currently on-going or being planned. New countries are expected to apply to GAVI for support by the May 2011 application deadline as well as future application rounds, and additional supply is therefore required.
Under the AMC legal framework, all suppliers which have registered to the AMC (please see how to register at http://www.vaccineamc.org/man_reg.html) can submit a proposal to UNICEF in response to this tender, even if products are in development and expected to become licensed and WHO pre-qualified and available for supply only within the next five years. Proposals submitted by pipeline manufacturers will be taken into consideration by UNICEF when deciding quantities to award to current suppliers, with regards to e.g. prices offered, the abiltiy to meet country product preferences, to meet demand and create a healthy market including multiple suppliers.
We therefore consider this meeting highly relevant for present and future manufacturers of pneumcoccal vaccines.
For more information regarding the meeting please contact Kathryn Dorgan at UNICEF Supply Divison: email@example.com